quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·42d
PRRelease
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

RARE· Ultragenyx Pharmaceutical Inc.
Health Care
Original source

Companies

  • RARE
    Ultragenyx Pharmaceutical Inc.
    Health Care

Recent analyst ratings

  • Mar 24UpdateGoldman$25.00
  • Oct 20UpdateWells Fargo$65.00
  • Jul 28UpdateH.C. Wainwright$80.00
  • May 28UpdateWilliam Blair-
  • Jun 6UpdateGoldman$67.00
  • Apr 22UpdateRBC Capital Mkts$77.00

Related

  • INSIDER3d
    SEC Form 4 filed by Kakkis Emil D
  • INSIDER3d
    SEC Form 4 filed by Huang Dennis Karl
  • INSIDER3d
    SEC Form 4 filed by Pinion John Richard
  • INSIDER3d
    SEC Form 4 filed by Parschauer Karah Herdman
  • INSIDER3d
    SEC Form 4 filed by Harris Erik
  • INSIDER3d
    SEC Form 4 filed by Crombez Eric
  • INSIDER3d
    SEC Form 4 filed by Horn Howard
  • INSIDER21d
    SEC Form 4 filed by Horn Howard
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022